Get the Stockscreener App
3.64
5.45%
-0.21
After Hours:
3.63
-0.01
-0.27%
Exagen Inc stock is traded at $3.64, with a volume of 291.31K.
It is down -5.45% in the last 24 hours and up +18.57% over the past month.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
See More
Previous Close:
$3.85
Open:
$3.75
24h Volume:
291.31K
Relative Volume:
0.79
Market Cap:
$87.94M
Revenue:
$66.58M
Net Income/Loss:
$-19.95M
P/E Ratio:
-3.9574
EPS:
-0.9198
Net Cash Flow:
$-14.27M
1W Performance:
+23.39%
1M Performance:
+18.57%
6M Performance:
-59.60%
1Y Performance:
-36.59%
1-Day Range:
$3.61
$3.85
1-Week Range:
$3.08
$4.13
52-Week Range:
$2.59
$12.23
Exagen Inc Stock (XGN) Company Profile
Name
Exagen Inc
Sector
Industry
Phone
(760) 560-1501
Address
1261 LIBERTY WAY, VISTA, CA
Compare XGN vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
3.64 | 93.02M | 66.58M | -19.95M | -14.27M | -0.9198 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-11-25 | Initiated | B. Riley Securities | Buy |
| Jul-30-25 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-23-25 | Initiated | Craig Hallum | Buy |
| Aug-05-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Apr-15-21 | Initiated | Canaccord Genuity | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cowen | Outperform |
| Oct-14-19 | Initiated | William Blair | Outperform |
View All
Exagen Inc Stock (XGN) Latest News
Exagen reaffirms $70M-$73M 2026 revenue guidance as it targets $600-$650 ASP over time - MSN
Exagen Inc. (XGN) reports Q1 loss, beats revenue estimates - MSN
Record revenue growth and higher test pricing keep Exagen (XGN) in focus despite ongoing losses - MSN
Earnings call transcript: Exagen Inc. beats Q1 2026 expectations, stock surges - Investing.com Nigeria
Exagen Inc. (NASDAQ:XGN) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
The Exagen Inc. (NASDAQ:XGN) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Exagen Targets $73 Million Revenue for 2026 as Test Volumes Surge - HarianBasis.co
Exagen Inc. (NASDAQ:XGN) Q1 2026 Earnings Call Transcript - Insider Monkey
TradingKey - TradingKey
Exagen Achieves Record Q1 Revenue Driven by AVISE CTD Adoption - HarianBasis.co
Analysts Offer Insights on Healthcare Companies: Exagen (XGN) and Liquidia Technologies (LQDA) - The Globe and Mail
Exagen (XGN) Q1 2026 Earnings Transcript - AOL.com
Exagen Inc stock (US30063K1051): Q1 revenue hits record $17.3M, up 12% - AD HOC NEWS
XGN Maintained by BTIG -- Price Target Lowered to $8.00 - GuruFocus
CCORF Maintains Exagen(XGN.US) With Buy Rating, Maintains Target Price $8 - Moomoo
BTIG Maintains Exagen(XGN.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
Exagen Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Exagen stock price target lowered to $8 by BTIG on valuation - Investing.com UK
Exagen Inc (XGN) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid Challenges - GuruFocus
Exagen (XGN) Reports Record Q1 Revenue of $17.3 Million, Up 12% Year-Over-Year - GuruFocus
Exagen | 10-Q: Q1 2026 Earnings Report - Moomoo
Number of shareholders of Exagen, Inc. – FWB:E08A - TradingView
Exagen Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:XGN) 2026-05-12 - Seeking Alpha
TD Cowen Maintains Exagen(XGN.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
Is Exagen (XGN) 30.9% Overvalued After Q1 2026 Earnings? EPS -0. - GuruFocus
Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Exagen Q1 earnings call highlights - MSN
XGN Maintains Revenue Forecast for 2026 - GuruFocus
Exagen Inc. Achieves Record $17.3 Million Q1 2026 Revenue - HarianBasis.co
Exagen (XGN) Achieves Strong Q1 Revenue Exceeding Expectations - GuruFocus
Exagen Q1 Earnings Call Highlights - Inkl
Exagen Inc. Reaffirms Earnings Guidance for the full year 2026 - marketscreener.com
Record Revenue Growth and Higher Test Pricing Keep Exagen (XGN) in Focus Despite Ongoing Losses - Yahoo Finance
XGN: Record revenue, higher ASP, and strong test volume growth drive positive 2026 outlook - TradingView
Exagen Hits Record Q1 Revenue, Signals Path to Profitability - BriefGlance
Exagen Releases Q1 2026 Financial Results - AlphaStreet
XGN: Q1 2026 revenue up 12% to $17.3M, with margin and ASP gains; guidance reaffirmed - TradingView
Exagen Inc. Reports Record Q1 2026 Revenue and AVISE CTD Average Selling Price - Minichart
Exagen Inc. (NASDAQ:XGN) Soars on Q1 2026 Earnings Beat as Record Revenue and Narrowed Loss Fuel Pre-Market Rally - ChartMill
EXAGEN INC. 1Q 2026: Revenue $17.31M, EPS $(0.17) — 10-Q Summary - TradingView
Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Exagen (NASDAQ: XGN) grows Q1 2026 revenue to $17.3M but remains loss-making - Stock Titan
Autoimmune test maker Exagen lifts prices, posts record $17.3M quarter - Stock Titan
Exagen reports Q1 2026 revenue $17.3M, adjusted EBITDA loss narrows to $2.16M - TradingView
XGN: Q1 2026 delivered record revenue, improved margins, and reaffirmed strong full-year guidance - TradingView
Exagen (XGN) posts record Q1 2026 revenue and higher AVISE CTD pricing - Stock Titan
Exagen Inc. Reports First Quarter 2026 Results - Caledonian Record
BRIEF-Exagen Inc. Q1 Revenue USD 17.306 Million Vs. IBES Estimate USD 16.4 Million - TradingView
Exagen Inc Stock (XGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):